IMMX — Immix Biopharma Cashflow Statement
0.000.00%
- $58.08m
- $40.40m
Annual cashflow statement for Immix Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.15 | -24.4 | -8.23 | -15.6 | -21.7 |
Depreciation | |||||
Non-Cash Items | 0.575 | 23.2 | 0.624 | 2.57 | 3.02 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.166 | -0.391 | 0.195 | 1.65 | 3.97 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.405 | -1.59 | -7.41 | -11.4 | -14.6 |
Capital Expenditures | 0 | -0.001 | 0 | -0.052 | -1.18 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | 0 | -0.001 | 0 | -0.052 | -1.18 |
Financing Cash Flow Items | 0 | — | 0.468 | -0.235 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 18.8 | 3.23 | 15.5 | 15.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.343 | 17.3 | -4.21 | 4.07 | 0.172 |